Wilby, J, Kainth, A, Hawkins, N et al. (9 more authors) (2005) Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation. Health technology assessment. ISSN 2046-4924
Abstract
The aim of this review was to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults. For the purposes of this review newer antiepileptic drugs (AEDs) included gabapentin (GBP) (Neurontin(R), Parke-Davis), lamotrigine (LTG) (Lamictal(R), GlaxoSmithKline), levetiracetam (LEV) (Keppra(R), UCB Pharma), oxcarbazepine (OXC) (Trileptal(R), Novartis Pharmaceuticals), tiagabine (TGB) [Gabatril(R), Cephalon (UK)], topiramate (TPM) (Topomax(R), Janssen-Cilag) and vigabatrin (VGB) (Sabril(R), Hoechst Marion Roussel). A concurrent review was performed by the West Midlands Health Technology Assessment Collaboration (WMHTAC), Birmingham, to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in children.
Metadata
Authors/Creators: |
|
---|---|
Keywords: | ADD-ON THERAPY, QUALITY-OF-LIFE, REFRACTORY PARTIAL EPILEPSY, NEWLY-DIAGNOSED EPILEPSY, COMPLEX PARTIAL SEIZURES, PLACEBO-CONTROLLED TRIAL, PARTIAL-ONSET SEIZURES, RESISTANT PARTIAL EPILEPSY, GAMMA-VINYL-GABA, VISUAL-FIELD DEFECTS |
Dates: |
|
Institution: | The University of York |
Academic Units: | The University of York > Faculty of Social Sciences (York) > Centre for Reviews and Dissemination (York) The University of York > Faculty of Social Sciences (York) > Centre for Health Economics (York) The University of York > Faculty of Sciences (York) > Health Sciences (York) |
Depositing User: | Pure (York) |
Date Deposited: | 07 Jun 2012 15:29 |
Last Modified: | 05 Feb 2024 00:19 |
Status: | Published |
Refereed: | Yes |
Related URLs: |